Ligand-Bound Gold Clusters for Antipsychotic Metabolic Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications, particularly atypical antipsychotics like olanzapine and clozapine, cause adverse effects such as obesity and metabolic disorders, with unclear underlying mechanisms, and existing treatments are inconclusive or contradictory.
Innovation Solution
The use of ligand-bound gold clusters, specifically those with a gold core and ligands such as L-cysteine derivatives, to treat adverse effects caused by atypical antipsychotics by forming stable complexes through covalent bonds, which are administered to counteract weight gain and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If atypical antipsychotics are used to treat psychiatric conditions, then therapeutic efficacy is improved, but metabolic adverse effects such as weight gain and lipid/glucose metabolism disorders occur
Solution Approach 1:
The patent introduces a third substance (metformin or GLP-1 receptor agonist) as an intermediary treatment to counteract the metabolic adverse effects of atypical antipsychotics. This mediator approach allows the antipsychotic to maintain its therapeutic efficacy while the intermediary drug specifically targets and mitigates the harmful metabolic effects, resolving the contradiction between treatment effectiveness and side effect management
Solution Approach 2:
The patent applies preliminary anti-action by administering metformin or GLP-1 receptor agonists before or concurrently with atypical antipsychotics to prevent metabolic adverse effects from developing. This proactive approach counteracts the harmful effects before they fully manifest, allowing patients to receive necessary psychiatric treatment without experiencing severe metabolic complications
2Object-affected harmful factors
If pharmacological adjunctive treatments such as H1R agonists or muscarinic antagonists are used to counteract antipsychotic-induced weight gain, then weight management may be improved, but treatment results become inconclusive or contradictory
Solution Approach 1:
The patent shifts from using receptor agonists/antagonists to using metformin or GLP-1 receptor agonists, which work through different physiological parameters (glucose metabolism, insulin sensitivity, appetite regulation). This parameter change provides more consistent and reliable treatment outcomes compared to the inconclusive results obtained with H1R agonists or muscarinic antagonists
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ligand-bound gold clusters effectively reduce or reverse weight gain and metabolic disorders in patients, providing a more effective treatment strategy than existing pharmacological interventions.
Implementation Method 1
forming stable complexes through covalent bonds
Data Source
AI summary
Ligand-bound gold clusters and compositions comprising the ligand-bound gold clusters are used for treating adverse effects caused by atypical antipsychotics and manufacturing a medicament for treatment of adverse effects caused by atypical antipsychotics. Methods for treating adverse effects caused by atypical antipsychotics.